InterMune, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for InterMune, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

InterMune, Inc.. The Group's principal activity is that of biotech company focused on development and commercialization of innovative therapies in pulmonology and hepatology. It has a product portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Actimmune and Pirfenidone; Actimmune is being evaluated in the INSPIRE Trial, a Phase III and Pirfenidone in the Phase II. The hepatology portfolio includes the lead HCV protease inhibitor PEG-Alfacon-1 in the Phase I, for Chronic Hepatitis C Virus Infections to further expand the limited treatments for HCV infections. The major customers include CuraScript Inc, Caremark, Nova Factor and Merck Medco.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report